NCT07545044 2026-04-22
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc.
Phase 2 Not yet recruiting
Shanghai JMT-Bio Inc.
Peking University Cancer Hospital & Institute
Hebei Medical University Fourth Hospital
Rutgers, The State University of New Jersey
Tianjin Medical University Cancer Institute and Hospital
University of Kansas Medical Center
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Henan Cancer Hospital
RenJi Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hospital Clinic of Barcelona